181 related articles for article (PubMed ID: 23522954)
41. Anti-angiogenic therapy: concept to clinic.
Young RJ; Reed MW
Microcirculation; 2012 Feb; 19(2):115-25. PubMed ID: 22078005
[TBL] [Abstract][Full Text] [Related]
42. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
Li JL; Sainson RC; Oon CE; Turley H; Leek R; Sheldon H; Bridges E; Shi W; Snell C; Bowden ET; Wu H; Chowdhury PS; Russell AJ; Montgomery CP; Poulsom R; Harris AL
Cancer Res; 2011 Sep; 71(18):6073-83. PubMed ID: 21803743
[TBL] [Abstract][Full Text] [Related]
43. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice.
Laird AD; Christensen JG; Li G; Carver J; Smith K; Xin X; Moss KG; Louie SG; Mendel DB; Cherrington JM
FASEB J; 2002 May; 16(7):681-90. PubMed ID: 11978732
[TBL] [Abstract][Full Text] [Related]
44. Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer.
Wu CL; Ping SY; Yu CP; Yu DS
Kaohsiung J Med Sci; 2012 Apr; 28(4):194-203. PubMed ID: 22453067
[TBL] [Abstract][Full Text] [Related]
45. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.
Mabuchi S; Terai Y; Morishige K; Tanabe-Kimura A; Sasaki H; Kanemura M; Tsunetoh S; Tanaka Y; Sakata M; Burger RA; Kimura T; Ohmichi M
Clin Cancer Res; 2008 Dec; 14(23):7781-9. PubMed ID: 19047105
[TBL] [Abstract][Full Text] [Related]
46. Refractory angiosarcoma of the breast with VEGFR2 upregulation successfully treated with sunitinib.
Silva E; Gatalica Z; Vranic S; Basu G; Reddy SK; Voss A
Breast J; 2015; 21(2):205-7. PubMed ID: 25639617
[No Abstract] [Full Text] [Related]
47. Sunitinib effects on the radiation response of endothelial and breast tumor cells.
El Kaffas A; Al-Mahrouki A; Tran WT; Giles A; Czarnota GJ
Microvasc Res; 2014 Mar; 92():1-9. PubMed ID: 24215790
[TBL] [Abstract][Full Text] [Related]
48. Angiogenesis as targeted breast cancer therapy.
Hayes DF; Miller K; Sledge G
Breast; 2007 Dec; 16 Suppl 2():S17-9. PubMed ID: 17707641
[TBL] [Abstract][Full Text] [Related]
49. EGFR- and VEGF(R)-targeted small molecules show synergistic activity in colorectal cancer models refractory to combinations of monoclonal antibodies.
Poindessous V; Ouaret D; El Ouadrani K; Battistella A; Mégalophonos VF; Kamsu-Kom N; Petitprez A; Escargueil AE; Boudou P; Dumont S; Cervera P; Fléjou JF; André T; Tournigand C; Chibaudel B; de Gramont A; Larsen AK
Clin Cancer Res; 2011 Oct; 17(20):6522-30. PubMed ID: 21880790
[TBL] [Abstract][Full Text] [Related]
50. Reappraising antiangiogenic therapy for breast cancer.
Kerbel RS
Breast; 2011 Oct; 20 Suppl 3(0 3):S56-60. PubMed ID: 22015294
[TBL] [Abstract][Full Text] [Related]
51. [Medical treatment of renal cell carcinoma].
Guy L; Bay JO; Bastide C; Mahammedi H; Bruyere F; Karsenty G
Prog Urol; 2013 Nov; 23(15):1225-37. PubMed ID: 24183081
[TBL] [Abstract][Full Text] [Related]
52. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
[TBL] [Abstract][Full Text] [Related]
53. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
[TBL] [Abstract][Full Text] [Related]
54. VEGF pathway-targeting drugs induce evasive adaptation by activation of neuropilin-1/cMet in colon cancer cells.
Tomida C; Yamagishi N; Nagano H; Uchida T; Ohno A; Hirasaka K; Nikawa T; Teshima-Kondo S
Int J Oncol; 2018 Apr; 52(4):1350-1362. PubMed ID: 29532881
[TBL] [Abstract][Full Text] [Related]
55. Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease.
Sims TL; Williams RF; Ng CY; Rosati SF; Spence Y; Davidoff AM
Surgery; 2008 Aug; 144(2):269-75. PubMed ID: 18656635
[TBL] [Abstract][Full Text] [Related]
56. The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.
Cassinelli G; Zuco V; Petrangolini G; De Cesare M; Tortoreto M; Lanzi C; Cominetti D; Zaffaroni N; Orlandi A; Passeri D; Meco D; Di Francesco AM; Riccardi R; Bucci F; Pisano C; Zunino F
Biochem Pharmacol; 2012 Jul; 84(2):163-71. PubMed ID: 22525722
[TBL] [Abstract][Full Text] [Related]
57. Anti-tumor effects of inactivated Sendai virus particles with an IL-2 gene on angiosarcoma.
Takehara Y; Satoh T; Nishizawa A; Saeki K; Nakamura M; Masuzawa M; Kaneda Y; Katayama I; Yokozeki H
Clin Immunol; 2013 Oct; 149(1):1-10. PubMed ID: 23886549
[TBL] [Abstract][Full Text] [Related]
58. Targeting of the breast cancer microenvironment with a potent and linkable oxindole based antiangiogenic small molecule.
Argyros O; Karampelas T; Varela A; Asvos X; Papakyriakou A; Agalou A; Beis D; Davos CH; Fokas D; Tamvakopoulos C
Oncotarget; 2017 Jun; 8(23):37250-37262. PubMed ID: 28422745
[TBL] [Abstract][Full Text] [Related]
59. Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib.
Huang Q; Zhou C; Chen X; Dong B; Chen S; Zhang N; Liu Y; Li A; Yao M; Miao J; Li Q; Wang Z
PLoS One; 2015; 10(10):e0141395. PubMed ID: 26513662
[TBL] [Abstract][Full Text] [Related]
60. [Therapeutic effects of Avastin on the murine hemangioendothelioma].
Xu ZQ; Liu Y; Wang YX; Zhang W; Zhao FY
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Feb; 41(1):105-8. PubMed ID: 19221576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]